Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature

<strong>Purpose:</strong> Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid leukemia (AML), but its rational utilization is compromised by the fact that neither the determinants of clinical response nor its mechanism of action are defined. Co-administra...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Craddock, C, Houlton, A, Quek, L, Ferguson, P, Gbandi, E, Roberts, C, Metzner, M, Garcia-Martin, N, Kennedy, A, Hamblin, A, Raghavan, M, Nagra, S, Dudley, L, Wheatley, K, McMullin, M, Pillai, S, Kelly, R, Siddique, S, Dennis, M, Cavenagh, J, Vyas, P
Định dạng:	Journal article
Ngôn ngữ:	English
Được phát hành:	American Association for Cancer Research 2017

Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature

Những quyển sách tương tự